US OptionsDetailed Quotes

ARMP241220C7500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Jaguar8
    Jaguar8
    Dec 19 06:06
    NEWS
    $Armata Pharmaceuticals (ARMP.US)$
    Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
    Thursday, 19th December at 7:00 am
    Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile
    LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Armata Pharmaceutic...
    Jaguar8
    Jaguar8
    Nov 14 15:33
    13D
    $Armata Pharmaceuticals (ARMP.US)$
    Armata Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Innoviva, Inc(85.2%),Innoviva Strategic Opportunities LLC(62.1%)
    Jaguar8
    Jaguar8
    Nov 12 06:06
    NEWS
    $Armata Pharmaceuticals (ARMP.US)$
    Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
    Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025
    LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology compan...
    Trytosaveabit
    Trytosaveabit
    Aug 14 05:42
    Watching for data!
    $Armata Pharmaceuticals (ARMP.US)$         The last patient had their final follow-up visit on August 7th, in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection. Armata anticipates topline data from the Tailwind study in the second half of 2024.
    2
    Trytosaveabit
    Trytosaveabit
    Jul 30 06:06
    Update
    $Armata Pharmaceuticals (ARMP.US)$ Reuters· 5 mins ago
    Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding From the U.S. Department of Defense to Support Ongoing Disarm Clinical Trial of AP-SA02
Read more